Successful Oral Administration of Insulin
Oral Insulin: SSNe Nano-Encapsulation and Oral Administration
Daniel R. DeBrouse, Ph.D, CEO, CSO Tamarisk Technologies, LLC Department of
Molecular Biology, Oklahoma Division of Pharmacology, February 2012
The importance of the realization of oral Insulin to mankind breaches all age groups, nationalities, homes, hospitals, pharmacies and clinics spanning the globe and echo’s throughout the thoughts of some of the most brilliant scientific minds. In fact, it’s difficult to imagine a single disciplined biochemist who has not on occasion dreamed of oral insulin. Oral Insulin is, in essence, the “Holy Grail” to the drug delivery scholar.
The pharmaceutical industry has literally spent billions of dollars in their quest for the seemingly ever elusive vehicle capable of transporting insulin safely through the gastrointestinal tract. And a tally of university funds dedicated, historically, to their own oral insulin endeavors would certainly stretch just as far. This one single feat, the provision of oral insulin, would impact our lives forever and revolutionize drug delivery as we know it, a task long overdue. Furthermore, the molecular after-shocks of a drug delivery vehicle for insulin would be felt globally impacting intramuscular (IM) and intravenous (IV) therapeutics as one once only IM/IV therapeutic peptide after another were fitted to its mechanism of transport.
To date, the difficulty with Insulin’s oral administration can be attributed to the necessity of the development of a transport system capable not only of transporting insulin through the harsh environment of the gastrointestinal tract but basolaterally as well within intestinal enterocytes. These are critical perquisites inhibited within the narrow scope of traditional drug delivery philosophy and have rather been realized within the understanding and wisdom of natural biological transport mechanisms and through the depths of imagination.
In the present study, we demonstrate the oral administration of Insulin in rodents at serum levels of significant clinical relevance, reproducibly, with an absolute bioavailability challenging to the IM administration of insulin (continued)...
Read the Full Report- Click Here
Related Articles
3rd Party Evaluation Study of Resveratrol Encapsulated within Tamarisk's SSNe Drug Delivery - Click Here
(SSNe) Serum-Specific Drug Transport- Click Here
Oral Insulin Report- Click Here
Oral Peptide YY 3-36 - Click Here
Oral Tumore Necrosis Factor - Coming Soon
Oral Herceptin - Coming Soon
Oral Pegylated Interferon - Coming Soon
For more information about Tamarisk's Serum Specifc, Tissue Specific, and Extended Release technologies, contact the DelivRX team today at licensing@tamarisktech.com or call our office at 405-279-1250.
The documents on this web site could include technical inaccuracies or typographical errors. Please report any errors to Tamarisk Technologies Customer Service.
